Naloxone OTC Switch Application On Horizon Thanks To $3.4M Funding From Purdue

Harm Reduction Therapeutics, which has sought funding for a US Rx-to-OTC new drug application, receives grant from Purdue Pharma that enables filing and launching the product in a targeted 100,000 retail locations within two years.

Harm Reduction Therapeutics Inc. estimates the first Rx-to-OTC switch for naloxone could hit the US market within 18 to 24 months, thanks to a $3.42m grant provided by opioid drug maker Purdue Pharma LP.

The low-cost nasal spray, an opioid antagonist indicated for complete or partial reversal of opioid overdose – including respiratory depression...